One study demonstrated that violacein induced apoptosis in HL60 cells (IC50 = 700 nM), a cancer cell line used as a model to study myeloid leukemia.
In a Cox regression model measuring time to leukemia diagnosis in months and correcting for age, initial treatment was not significant in the model (n = 5,790), (-2 log likelihood = 270.52, chi square = 3.65, 2 degrees of freedom, p =.456).
This experimental model system offers to the hematologist and clinical pharmacologist a means to study genetic differences in toxic chemical depression of the bone marrow, as well as a potential model to study aplastic anemia and leukemia explainable on a single-gene basis.
In addition, to fully explore cancer in a mouse model, it is necessary to look beyond solid tumors to leukemia models.
Next, we used a transplantable BCR-ABL-driven acute lymphoblastic leukemia (ALL) mouse model to assess CY's in vivo activity.
The above studies demonstrated that CRISPR can be used to engineer structural variants such as insertions, deletions, mutations and translocations, as well as to model leukemia.
Our rationale for developing a xenogeneic leukemia model, as opposed to a murine model, to test GDTc therapy is because the human Vγ9Vδ2 GDTc subset, which is cytotoxic to Ph+ leukemia cells, does not exist in mice [43], [44].
Although the approaches described here are not the ideal models to study myeloid leukemia, each of them has their own advantages and their integration compensates for their limitations: 1) The use of cells derived from patients harbouring a RUNX1 mutation but who have not yet developed leukemia allow us to observe effects, largely due to changes in RUNX1 dosage.
The question arises: Is it possible to translate the observations of DAC in this mouse model of leukemia to the clinical treatment of patients with leukemia?
Leukemic stem cells (LSCs) are cells that can give rise to leukemia in transplant murine models, and therefore have self-renewal property.
